Latest Breaking News On - Phase 3 sonia trial - Page 1 : comparemela.com

Sarah Sammons, MD, discusses whether CDK4/6 inhibitors should be considered a standard first line treatment within hormone receptor–positive, HER2-negative advanced breast cancer according to primary results from the phase 3 SONIA trial.

Sarah sammonsDana farber cancer instituteMetastatic breast cancer programEstrogen receptor positiveEr2 negative advanced or metastatic breast cancerCdk4 6 inhibitorsPhase 3 sonia trialHormone receptor hr positiveEr2 negative advanced breast cancer